论文部分内容阅读
为评估重组粒细胞-巨噬细胞克隆刺激因子(GM-CSF)是否有刺激恶性淋巴细胞增生性疾病伴血细胞减少患者的骨髓造血作用,作者对11例患者应用重组人类GM-CSF进行了1期临床形究。5例为慢性淋巴细胞白血病(CLL)/弥漫性分化良好淋巴细胞淋巴瘤,2例为T细胞瘤,另外,急性淋巴细胞白血病、巨球蛋白血症、弥漫性混合性淋巴细胞瘤、T-γ-淋巴细胞增生性疾病各1例。10例患者由
To assess whether GM-CSF stimulates bone marrow hematopoiesis in patients with malignant lymphoproliferative disorders and cytopenia, we performed a phase I trial of 11 human patients with recombinant human GM-CSF Clinical research. 5 cases of chronic lymphocytic leukemia (CLL) / diffuse well-differentiated lymphocytic lymphoma, 2 cases of T cell tumor, in addition, acute lymphoblastic leukemia, macroglobulinemia, diffuse mixed lymphocytoma, T- γ-lymphocytic proliferative disease in 1 case. 10 patients by